Article
Cell Biology
Huimin Sun, Xing Wei, Changchun Zeng
Summary: Xp11 translocation renal cell carcinoma (tRCC) is a newly identified subtype of RCC that urgently requires effective prevention and treatment strategies. Autophagy plays a crucial role in tRCC and could potentially serve as a therapeutic target.
MOLECULAR AND CELLULAR BIOCHEMISTRY
(2021)
Article
Oncology
Xiang Dong, Yuxin Chen, Jun Pan, Wenliang Ma, Peng Zhou, Ming Chen, Hongqian Guo, Weidong Gan
Summary: This study found that TFE3 expression in RCC is associated with tumor progression and poor prognosis.
FRONTIERS IN ONCOLOGY
(2022)
Article
Acoustics
Wenliang Ma, Fan Zhang, Haifeng Huang, Wei Wang, Yiqi Zhu, Yanwen Lu, Hongqian Guo, Weidong Gan
Summary: Conventional ultrasound (US) and contrast-enhanced US (CEUS) can be used to differentiate Xp11.2 translocation renal cell carcinoma (Xp11.2 tRCC) from other common renal cell carcinoma (RCC) subtypes. Xp11.2 tRCC is more common in young women and has hypo- and isoechoic lesions with a higher frequency of calcification. CEUS features include synchronous wash-in, iso-enhancement at peak, and fast wash-out.
JOURNAL OF ULTRASOUND IN MEDICINE
(2022)
Article
Pediatrics
Kaihang Yang, Yuhao Ma, Shuyang Dai, Rui Dong
Summary: Xp11.2 tRCC is a rare subtype of renal cell carcinoma in children and adults, characterized by TFE3 gene rearrangements. We reported a rare case of a 6-year-old male patient with Xp11.2 tRCC and retroperitoneal metastasis. The patient achieved a good therapeutic outcome after undergoing several surgeries. This case can provide reference and guidance for pediatric urologists and oncologists in recognizing and diagnosing rare renal cell carcinoma in children.
FRONTIERS IN PEDIATRICS
(2023)
Article
Oncology
Shintaro Funasaki, Sally Mehanna, Wenjuan Ma, Hidekazu Nishizawa, Yasuhiko Kamikubo, Hiroshi Sugiyama, Shuji Ikeda, Takanobu Motoshima, Hisashi Hasumi, W. Marston Linehan, Laura S. Schmidt, Chris Ricketts, Toshio Suda, Yuichi Oike, Tomomi Kamba, Masaya Baba
Summary: In this study, researchers discovered that the PRCC-TFE3 fusion protein controls HMOX1 expression to confer chemoresistance in TFE3-RCC cells. They identified a novel compound called Chb16 that inhibits PRCC-TFE3-dependent transcription of HMOX1 and demonstrated its potential therapeutic effect for treating TFE3-RCC.
Article
Oncology
Nail Paksoy, Selcuk Erdem, Mert Karaca, Naziye Ak, Metin Pehlivan, Inci K. Yirgin, Yasemin Ozluk, Feza Ekiz, Deniz Tural, Meltem Ekenel, Faruk Ozcan, Mert Basaran
Summary: TFE3-related renal cell carcinomas are rare in adults and have a poor prognosis, with no standardized treatment protocol currently in place. This case report highlights a young woman with rapidly progressing metastatic TFE3(+) renal cell carcinoma, showing unexpected rapid progression under consecutive immunotherapy and a need for more standardized treatment protocols and new agents for management.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE
(2022)
Article
Oncology
Ning Liu, Yi Chen, Lei Yang, Qiancheng Shi, Yanwen Lu, Wenliang Ma, Xiaodong Han, Hongqian Guo, Dongmei Li, Weidong Gan
Summary: The study demonstrates that androgen and androgen receptor (AR) play a facilitating role in the progression of Xp11.2 tRCC and may serve as a novel therapeutic target for Xp11.2 tRCC.
CLINICAL AND TRANSLATIONAL MEDICINE
(2022)
Review
Pathology
Kristina Doytcheva, Alexander J. Gallan, Peng Wang, Pankhuri Wanjari, Jeremy Segal, Tatjana Antic
Summary: This article presents four cases of cystic renal masses with a MED15::TFE3 gene fusion detected by RNAseq, which mimic multilocular cystic neoplasm of low malignant potential. Clinicopathologic and outcomes data were collected for analysis. The tumors showed extensive cystic changes with cells lining the cysts' septa having clear or minimally granular cytoplasm and inconspicuous nucleoli. Focally, mass-forming aggregates of malignant cells were found between the septae. Immunohistochemistry showed positive staining for TFE3, MelanA, and P504S, while CAIX and CK7 were negative. RNA sequencing confirmed the MED15::TFE3 gene fusion. The patients had a good prognosis after partial nephrectomy, with no evidence of disease during the follow-up period.
Article
Oncology
Hui-Zhi Zhang, Su-Ying Wang
Summary: Alpha-fetoprotein (AFP) is a useful tumor marker for hepatocellular carcinomas and yolk sac tumors. Rare extrahepatic visceral malignancies may be associated with AFP production, such as hepatoid adenocarcinoma. Producing AFP renal cell carcinoma is a rare entity.
CURRENT PROBLEMS IN CANCER
(2021)
Article
Urology & Nephrology
Jiale Zhou, Ling Zhao, Zhaolin Yang, Yonghui Chen, Xiaorong Wu, Wei Xue
Summary: This study reported the clinicopathological features and mid- to long-term oncologic results of Xp11.2 translocation RCC. The incidence of Xp11.2 translocation RCC was relatively low and patients in early stage had similar prognosis to typical RCC, while late-stage patients had poor oncological outcomes.
Article
Oncology
Haiyang Yang, Xiang Dong, Xinghe Pan, Wenliang Ma, Jun Pan, Hongqian Guo, Weidong Gan
Summary: TFE3-rearranged renal cell carcinoma is a rare subtype of renal tumor that primarily affects young women and is characterized by early metastasis and a poor prognosis. This case study reports a 29-year-old woman with TFE3-rearranged RCC, who initially presented with painless gross hematuria, and achieved favorable treatment outcomes.
FRONTIERS IN ONCOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Jee Soo Park, Myung Eun Lee, Won Sik Jang, Jongchan Kim, Se Mi Park, Won Sik Ham
Summary: This study identifies a potential biomarker, PIK3R2, for aggressive Xp11.2 tRCC and recommends a targeted drug, LY294002, based on its molecular pathophysiology.
Article
Oncology
Yan Ge, Xingtao Lin, Qingling Zhang, Danyi Lin, Luqiao Luo, Huiling Wang, Zhi Li
Summary: This study analyzed cases of Xp11.2 translocation RCC and identified a novel VCP-TFE3 fusion gene, showing worse prognosis compared to other fusion types. The integration of morphological, immunohistochemical, and molecular methods is essential for precise diagnosis and optimal management of malignant tumors.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Xiaofan Lu, Nassim Tawanaie Pour Sedehi, Xiaoping Su, Fangrong Yan, Omar Alhalabi, Nizar M. Tannir, Gabriel G. Malouf
Summary: The prevalence of MiT family translocation renal cell carcinomas (TRCC) is higher in Asian and Black patients compared to White patients, and these tumors in Asian and Black patients have distinct transcriptional features and poor outcomes.
Review
Biochemistry & Molecular Biology
Audrey Simonaggio, Damien Ambrosetti, Virginie Verkarre, Marie Auvray, Stephane Oudard, Yann-Alexandre Vano
Summary: MiTF/TFE translocation renal cell carcinoma (tRCC) is a rare and aggressive subtype of RCC, which is more prevalent in the pediatric population and represents 4% of all RCCs in adults. The diagnosis of tRCC involves translocations of genes such as TFE3, TFEB or MITF. TFE break-apart fluorescent in situ hybridization (FISH) is considered the gold standard for diagnosis. tRCC exhibits heterogeneous clinical behaviors and is more aggressive in adults. Effective treatment options for metastatic tRCC are limited, highlighting the need for better therapeutic approaches. Comprehensive genetic sequencing analyses have provided insights into the biological heterogeneity of tRCC, aiding in the development of more effective treatments.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Oncology
L. E. A. Delsin, G. M. Roberto, P. F. Fedatto, E. E. Engel, C. A. Scrideli, L. G. Tone, M. S. Brassesco
PATHOLOGY & ONCOLOGY RESEARCH
(2019)
Article
Oncology
Maria Sol Brassesco, Julia Alejandra Pezuk, Karina Bezerra Salomao, Gabriela Molinari Roberto, Carlos Alberto Scrideli, Luiz Gonzaga Tone
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY
(2018)
Article
Oncology
Karina Bezerra Salomao, Gustavo Alencastro Veiga Cruzeiro, Ricardo Bonfim-Silva, Lenisa Geron, Fernando Ramalho, Fabiano Pinto Saggioro, Luciano Neder Serafini, Daniel Antunes Moreno, Rosane Gomes de Paula Queiroz, Simone dos Santos Aguiar, Izilda Cardinalli, Jose Andres Yunes, Silvia Regina Brandalise, Maria Sol Brassesco, Carlos Alberto Scrideli, Luiz Gonzaga Tone
JOURNAL OF NEURO-ONCOLOGY
(2018)
Article
Pathology
Gabriela Molinari Roberto, Edgard Eduard Engel, Carlos Alberto Scrideli, Luiz Gonzaga Tone, Maria Sol Brassesco
PATHOLOGY RESEARCH AND PRACTICE
(2018)
Review
Oncology
Lara Elis Alberici Delsin, Karina Bezerra Salomao, Julia Alejandra Pezuk, Maria Sol Brassesco
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2019)
Letter
Medical Laboratory Technology
Gabriela Molinari Roberto, Edgard Eduard Engel, Luiz Gonzaga Tone, Maria Sol Brassesco
CLINICA CHIMICA ACTA
(2019)
Review
Oncology
G. M. Viera, K. B. Salomao, G. R. de Sousa, M. Baroni, L. E. A. Delsin, J. A. Pezuk, M. S. Brassesco
CLINICAL & TRANSLATIONAL ONCOLOGY
(2019)
Review
Clinical Neurology
M. F. Candido, G. C. Baldissera, M. Medeiros, K. Umezawa, Maria Sol Brassesco
CHILDS NERVOUS SYSTEM
(2020)
Article
Chemistry, Analytical
Joao H. Uliana, Diego R. T. Sampaio, Guilherme S. P. Fernandes, Maria S. Brassesco, Marcello H. Nogueira-Barbosa, Antonio A. O. Carneiro, Theo Z. Pavan
Article
Pharmacology & Pharmacy
Graziella Ribeiro de Sousa, Gabriela Maciel Vieira, Pablo Ferreira das Chagas, Julia Alejandra Pezuk, Maria Sol Brassesco
PHARMACOLOGICAL RESEARCH
(2020)
Article
Clinical Neurology
Marcela de Oliveira Silva, Graziella Ribeiro de Sousa, Sarah Capelupe Simoes, Patricia Nicolucci, Edwin Tamashiro, Fabiano Saggioro, Ricardo Santos de Oliveira, Maria Sol Brassesco
Summary: POH demonstrates effective anti-medulloblastoma effects in vitro and shows synergistic combinations with other conventional therapeutics; in vivo experiments confirm that POH reduces tumor volume when administered intraperitoneally, but its effect on orthotopic tumors remains unclear.
CHILDS NERVOUS SYSTEM
(2021)
Review
Biochemistry & Molecular Biology
Mariana Medeiros, Marina Ferreira Candido, Elvis Terci Valera, Maria Sol Brassesco
Summary: Despite advances in understanding pediatric CNS malignancies, the prognosis remains poor. NF-kB pathway plays a key role in cancer, and research on its dysregulation in glioma, medulloblastoma, and ependymoma provides insights into potential therapeutic targets for improving cure rates and reducing side effects.
CELLULAR AND MOLECULAR LIFE SCIENCES
(2021)
Review
Genetics & Heredity
Jaqueline Carvalho de Oliveira, Carolina Mathias, Veronica Cristina Oliveira, Julia Alejandra Pezuk, Maria Sol Brassesco
Summary: miR-708 plays a dual role in tumors, acting as both an oncogenic and tumor suppressor molecule. It is associated with various genes and signaling pathways related to tumor development and suppression. In a clinical setting, miR-708 can serve as a reliable diagnostic and prognostic marker. However, its multitarget nature, opposing roles in different tumors, as well as limited experimental data and delivery strategies, hinder its potential as a targeted therapy for tumors.
Article
Clinical Neurology
Maria Sol Brassesco, Gabriela Molinari Roberto, Lara Elis Delsin, Gabriel Carlos Baldissera, Mariana Medeiros, Kazuo Umezawa, Luiz Gonzaga Tone
Summary: The results of this study demonstrate that dehydroxymethylepoxyquinomicin (DHMEQ) can inhibit the growth and invasiveness of pediatric glioblastomas and improve treatment response to drugs and radiotherapy. These findings strengthen the potential usefulness of NF-kB inhibition in overcoming this incurable disease.
CHILDS NERVOUS SYSTEM
(2023)
Review
Pharmacology & Pharmacy
Marina Ferreira Candido, Mariana Medeiros, Luciana Chain Veronez, David Bastos, Karla Laissa Oliveira, Julia Alejandra Pezuk, Elvis Terci Valera, Maria Sol Brassesco
Summary: Childhood cancer is rare but has a high mortality rate, with one child dying of cancer every 3 minutes. In this study, the expression patterns of a selected group of kinases in pediatric solid tumors were analyzed, and their correlation with clinical outcomes was evaluated. Additionally, the vulnerability of different cancer cell lines to kinase inhibition and the availability of kinase-targeted compounds for pediatric tumors were investigated. The study also discussed the challenges in translating these findings into clinical options.